tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Exelixis price target lowered to $43 from $46 at RBC Capital
PremiumThe FlyExelixis price target lowered to $43 from $46 at RBC Capital
9d ago
Merck, Eisai announce results on Phase 3 Litespark-011 trial of Welireg
Premium
The Fly
Merck, Eisai announce results on Phase 3 Litespark-011 trial of Welireg
10d ago
Merck announces results from Phase 3 Litespark-022 trial
Premium
The Fly
Merck announces results from Phase 3 Litespark-022 trial
10d ago
Merck initiated with an Outperform at RBC Capital
PremiumThe FlyMerck initiated with an Outperform at RBC Capital
15d ago
Here Are 3 Technology ETFs with At Least 20% Upside Potential
Premium
Market News
Here Are 3 Technology ETFs with At Least 20% Upside Potential
16d ago
Merck announces new operating structure in Human Health business
Premium
The Fly
Merck announces new operating structure in Human Health business
16d ago
Merck announces new Enflonsia data from SMART trial
PremiumThe FlyMerck announces new Enflonsia data from SMART trial
20d ago
FDA to begin requiring on clinical trial
Premium
The Fly
FDA to begin requiring on clinical trial
21d ago
FDA to begin requiring one clinical trial in drug approvals
Premium
The Fly
FDA to begin requiring one clinical trial in drug approvals
21d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100